Bayer Subsidiary Gets Fast-track Status for Parkinson's Trea

By David Sachs


A Bayer-owned drug developer received special fast-track status from U.S. regulators for its Parkinson's disease treatment following positive phase-1 trials.

The German...

Related Keywords

Germany , German , Christian Rommel , David Sachs , Drug Administration , Bluerock Therapeutic , Regenerative Medicine Advanced Therapy , Dow Jones ,